Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)

Janux Therapeutics (JANX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $77.3 million as the latest value for Q1 2021.

  • Quarterly Preferred Stock Liabilities changed N/A to $77.3 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $77.3 million through Mar 2021, changed N/A year-over-year, with the annual reading at $21.6 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q1 2021 was $77.3 million at Janux Therapeutics, up from $21.6 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $77.3 million in Q1 2021, with the low at $17.1 million in Q2 2020.